TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 573185

Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 48
Study: 31152533

Group type: EXPERIMENTAL
Intervention: Vortex massages and physical training procedures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Individually selected training
Number of subjects: 50
Study: 26467810

Group type: EXPERIMENTAL
Intervention: Closing wedge high tibial osteotomy (CW HTO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Opening wedge high tibial osteotomy (OW HTO)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both techniques (CW and OW HTO)
Number of subjects: 70
Study: 26340658

Group type: EXPERIMENTAL
Intervention: Nebulised tobramycin (300 mg twice daily for 3 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nebulised tobramycin
Number of subjects: 35
Study: 23879671

Group type: EXPERIMENTAL
Intervention: Azithromycin (1500 mg/week for four weeks)
Number of subjects: 10
Study: 21278137

Group type: COMPARATOR
Intervention: Younger control (Y-C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Heart failure functional class III (HF-III)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Heart failure functional class II (HF-II)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cardiac output or Δ[THb](FC)
Number of subjects: 101
Study: 19180378

Group type: EXPERIMENTAL
Intervention: Understanding of randomization in clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 0
Study: 16721298

Group type: EXPERIMENTAL
Intervention: PLF
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: PLIF
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: PLF+PLIF
Number of subjects: 167
Study: 15541405

Group type: EXPERIMENTAL
Intervention: Standard dose of levonorgestrel (LNG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single 0.75-mg dose of levonorgestrel (half dose)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 11704378

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9048281

Group type: EXPERIMENTAL
Intervention: Dipyridamole (group 1, n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dobutamine (group 2, n = 26)
Number of subjects: 50
Study: 7526868

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) substance P (SP) levels in FMS patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 32
Study: 2564505

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline ethylenediamine (aminophylline), 7 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single oral dose of theophylline (375 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infusion of theophylline ethylenediamine
Number of subjects: 20
Study: 170949

Group type: EXPERIMENTAL
Intervention: Cynarin (3,5‐dihydroxy‐1,4‐bis‐(3,4‐dihydroxy‐cinnamoyloxy)‐cyclohexan‐carbonic acid) for 50 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 50 days
Number of subjects: 60
Study: 30716942

Group type: EXPERIMENTAL
Intervention: Synbiotic group (SG): 40 g of extruded sorghum plus 100 mL of unfermented probiotic milk
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG): 40 g of extruded corn plus 100 mL of pasteurized milk
Number of subjects: 58
Study: 28747487

Group type: EXPERIMENTAL
Intervention: Glycemic Load (GL)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids (PUFAs)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Insoluble Fiber
Number of subjects: 269
Study: 25934170

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Online CBT
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 174
Study: 23882452

Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splint in situ
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nights without the stabilization splint in situ
Number of subjects: 10
Study: 21365345

Group type: EXPERIMENTAL
Intervention: Strength Training (ST), n=10
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Power Training (PT), n=10
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (C), n=5
Number of subjects: 25
Study: 19324952

Group type: EXPERIMENTAL
Intervention: COPD cases (male)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: COPD cases (female)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Controls (male)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Controls (female)
Number of subjects: 894
Study: 17419259

Group type: EXPERIMENTAL
Intervention: Octreotide (continuous infusion for 48 hours)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (continuous infusion for 48 hours)
Number of subjects: 68
Study: 15266769

Group type: EXPERIMENTAL
Intervention: 15 mg of meloxicam (Group M, n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (Group P, n = 25)
Number of subjects: 52
Study: 11504270

Group type: EXPERIMENTAL
Intervention: 50 mg oral [14C]omapatrilat
Number of subjects: 12

Group type: COMPARATOR
Intervention: 20 mg intravenous [14C]omapatrilat
Number of subjects: 12
Study: 9655309

Group type: EXPERIMENTAL
Intervention: Unexplained DVT
Number of subjects: 326

Group type: COMPARATOR
Intervention: Secondary DVT
Number of subjects: 326
Study: 7826786

Group type: EXPERIMENTAL
Intervention: nizatidine 6 mg kg‐1 at 21:00 and placebo at 06:30
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: placebo at 21:00 and nizatidine 6 mg kg‐1 at 06:30
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: nizatidine 3 mg kg‐1 at 21:00 and 06:30
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo‐placebo (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: placebo‐nizatidine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: nizatidine‐nizatidine
Number of subjects: 104
Study: 3258578

Group type: EXPERIMENTAL
Intervention: Large varices at endoscopy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hepatic vein pressure gradient
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Previous variceal bleeding
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Modified Child‐Turcotte's criteria and incapacitation index
Number of subjects: 58
Study: 30236867

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27481017

Group type: EXPERIMENTAL
Intervention: Simethicone administration
Number of subjects: 127
Study: 24725355

Group type: EXPERIMENTAL
Intervention: Condoms plus emergency contraception pills (ECP) (Levonorgestrel)
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1562
Study: 23830355

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily
Number of subjects: 715

Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 715
Study: 20628385

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Gemcitabine alone (G)
Number of subjects: 84
Study: 18250132

Group type: EXPERIMENTAL
Intervention: Aerobic capacity (maximal oxygen uptake/VO2 max) measured with a bicycle ergometer exercise test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (L/min, mL/min/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overall disease activity assessed with Systemic Lupus Activity Measure (SLAM) and modified SLE-DAI
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overall organ damage assessed with SLICC/(ACR)-DI
Number of subjects: 34

Group type: COMPARATOR
Intervention: Health-related quality of life (HRQL) assessed with the 36-item Short-form health-survey (SF-36)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Physical activity assessed with a self-assessed question
Number of subjects: 34
Study: 16377065

Group type: EXPERIMENTAL
Intervention: 5 x 1000 IU hCG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 x 500 IU hCG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 x 250 mg progesterone
Number of subjects: 36
Study: 12686241

Group type: EXPERIMENTAL
Intervention: Low-cost combination (hydroxypropyl methylcellulose 2% (Ocucoat) and Ringer's solution)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Expensive combination (sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) and BSS Plus)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (low-cost and expensive combinations)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Expensive combination (Viscoat and BSS Plus)
Number of subjects: 45
Study: 11095133

Group type: EXPERIMENTAL
Intervention: Laser trabeculodissection (LTD) using a 193 nm photopolishing, scanning excimer laser system
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Laser trabeculodissection (LTD)
Number of subjects: 8
Study: 9370845

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.20 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cisatracurium 0.15 mg.kg‐1
Number of subjects: 60
Study: 7519694

Group type: EXPERIMENTAL
Intervention: Sustained release verapamil and ACE inhibition by trandolapril
Number of subjects: 0
Study: 2885187

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: morphine 0.2 mg/kg
Number of subjects: 50
Study: 31062377

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk (0.2 mL of mother's colostrum or milk prior to gavage feeding)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk
Number of subjects: 200
Study: 30238798

Group type: EXPERIMENTAL
Intervention: Whey ready-to-use supplementary food (RUSF)
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Soy ready-to-use supplementary food (RUSF)
Number of subjects: 2259
Study: 27068872

Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction (index <1.67)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal endothelial function (index ≥1.67)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus at baseline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of diabetes mellitus
Number of subjects: 70
Study: 25639278

Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT)
Number of subjects: 462
Study: 23107871

Group type: EXPERIMENTAL
Intervention: Daily oral 150 mg of vismodegib for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of 400 mg of moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for vismodegib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for moxifloxacin
Number of subjects: 0
Study: 21347968

Group type: EXPERIMENTAL
Intervention: Supported exercise programme (3 60-min supported + 2 unsupported sessions per week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care programme (advice to exercise at moderate to high intensity for 30 min five times a week)
Number of subjects: 19
Study: 18303468

Group type: EXPERIMENTAL
Intervention: Surgery versus conservative treatments (17 NRSs and 8 RCTs)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Surgery with fusion versus surgery without fusion (17 NRSs and 3 RCTs)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Instrumented fusion versus noninstrumented fusion (15 NRSs and 8 RCTs)
Number of subjects: 43
Study: 16724235

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 124

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEpo)
Number of subjects: 124
Study: 12559135

Group type: EXPERIMENTAL
Intervention: Korean Symptom Checklist
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Health Locus of Control Scale
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Self‐efficacy Scale
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Self‐esteem Scale
Number of subjects: 2052
Study: 10895921

Group type: EXPERIMENTAL
Intervention: Backboard padded with a gurney mattress and eggcrate foam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backboard padded with a gurney mattress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backboard padded with a folded blanket
Number of subjects: 0

Group type: COMPARATOR
Intervention: Backboard alone
Number of subjects: 0
Study: 8923359

Group type: EXPERIMENTAL
Intervention: sCT 100 IU/day and calcium (Ca) 500 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calcium (Ca) alone
Number of subjects: 32
Study: 1557921

Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 120
Study: 3535473

Group type: EXPERIMENTAL
Intervention: Diltiazem therapy for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31591010

Group type: EXPERIMENTAL
Intervention: Kinematic Alignment (KA) TKA
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mechanical Alignment (MA) TKA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both KA and MA TKA
Number of subjects: 41
Study: 30352059

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention targeting physical activity, diet, and behavior modification for six months.
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group receiving prompt infertility care as usual.
Number of subjects: 577
Study: 27207552

Group type: EXPERIMENTAL
Intervention: tRES-HESP coformulation
Number of subjects: 29
Study: 25034409

Group type: EXPERIMENTAL
Intervention: EBP training program (one day face-to-face training with online support)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study: 23180065

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22432517

Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre (GS) supplementation at 500 mg per day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15960558

Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants (primarily fluoxetine, duration 6 to 12 weeks)
Number of subjects: 171

Group type: COMPARATOR
Intervention: First-generation antidepressants (including placebo, phenelzine, and imipramine, N = 420)
Number of subjects: 171
Study: 12638101

Group type: EXPERIMENTAL
Intervention: Balance and gait analysis
Number of subjects: 20
Study: 10338172

Group type: EXPERIMENTAL
Intervention: 3 mg morphine + 30 mg ketorolac (group KM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac (group K60)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 mg morphine (group M)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac (group K30)
Number of subjects: 100
Study: 7796236

Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Synchronous Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 40
Study: 1938398

Group type: EXPERIMENTAL
Intervention: Silver-impregnated activated charcoal xerodressing (SIAX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (phase-adapted therapy using diverse topical modalities)
Number of subjects: 40
Study: 7229121

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Histamine (10 microgram/min for 20 minutes)
Number of subjects: 6
Study: 31299352

Group type: EXPERIMENTAL
Intervention: FENO-based management
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: FENO group
Number of subjects: 220
Study: 30222962

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obeticholic acid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline NAS > 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline triglyceride level ≤ 154 mg/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline international normalized ratio ≤ 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline aspartate aminotransferase level ≤ 49 U/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease in alanine aminotransferase level at week 24 by 17 U/L or more
Number of subjects: 0
Study: 27398920

Group type: EXPERIMENTAL
Intervention: Horizontal Drop Jump (HDJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vertical Drop Jump (VDJ)
Number of subjects: 18
Study: 26378687

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8505
Study: 22760341

Group type: EXPERIMENTAL
Intervention: 3-day combined clavulanate/amoxicillin preparation
Number of subjects: 97

Group type: COMPARATOR
Intervention: 10-day amoxicillin treatment
Number of subjects: 97
Study: 21951412

Group type: EXPERIMENTAL
Intervention: SMART program (standard medical management for secondary prevention of ischemic stroke)
Number of subjects: 4074
Study: 19678461

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Guided meditation
Number of subjects: 167

Group type: COMPARATOR
Intervention: Active control (visits from hospice-trained volunteers)
Number of subjects: 167
Study: 17725758

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 40
Study: 15001195

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) + diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 120
Study: 11145795

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 351

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 351
Study: 9695299

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms, twice a day for 3 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg, twice a day for 3 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Salmeterol (25 micrograms, twice a day for 3 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (twice a day for 3 weeks)
Number of subjects: 43
Study: 7912042

Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic blocker
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 2809777

Group type: EXPERIMENTAL
Intervention: 100-g carbohydrate meal
Number of subjects: 66

Group type: COMPARATOR
Intervention: 50-g glucose load (Glucola)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Glucola
Number of subjects: 66
Study: 342621

Group type: EXPERIMENTAL
Intervention: Inactivated whole influenza A/New Jersey/8/76 virus vaccine (graded doses of 4-61 micrograms of hemagglutinin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trivalent vaccine (A/New Jersey/76, A/Victoria/75, B/Hong Kong/73)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 61-microgram dose of hemagglutinin
Number of subjects: 0
Study: 30556428

Group type: EXPERIMENTAL
Intervention: Social media parenting intervention (Facebook)
Number of subjects: 24

Group type: COMPARATOR
Intervention: In-person parenting intervention
Number of subjects: 24
Study: 28800090

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (1680 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25990482

Group type: EXPERIMENTAL
Intervention: 400 mcg misoprostol sublingually
Number of subjects: 500

Group type: COMPARATOR
Intervention: 10 units oxytocin intramuscularly
Number of subjects: 500
Study: 23353175

Group type: EXPERIMENTAL
Intervention: Microscopic varicocelectomy (group A, n=130)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional Palomo varicocelectomy (group B, n=130)
Number of subjects: 260
Study: 21321030

Group type: EXPERIMENTAL
Intervention: Intervention group (shared reading activities modeled by nurses, supported by parent information and free books)
Number of subjects: 552
Study: 19595145

Group type: EXPERIMENTAL
Intervention: Teprenone (intervention group, n=45)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=47)
Number of subjects: 92
Study: 17012719

Group type: EXPERIMENTAL
Intervention: Air abrasion followed by acid etching (Group II)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acid etching (Group I)
Number of subjects: 16
Study: 12753338

Group type: EXPERIMENTAL
Intervention: Reinforced group (n = 114) received IFN-2b 6 million units (MU) thrice weekly (TIW) and ribavirin for 48 weeks
Number of subjects: 231

Group type: COMPARATOR
Intervention: Nonreinforced group (n = 117) received IFN-2b 3 MU TIW and ribavirin for 24 weeks
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Reinforced group (n = 80)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Nonreinforced group (n = 80)
Number of subjects: 231
Study: 11023017

Group type: EXPERIMENTAL
Intervention: Life Skills Training (cognitive-behavioral skills-training prevention program) during junior high school
Number of subjects: 447

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 447
Study: 9354208

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate b.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate b.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8371915

Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006%)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 22
Study: 2873440

Group type: EXPERIMENTAL
Intervention: Inhaled platelet activating factor (PAF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lyso‐PAF (inactive precursor of PAF)
Number of subjects: 8
Study: 31802559

Group type: EXPERIMENTAL
Intervention: Curcumin (1,500 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70